Sucampo Pharmaceuticals acquires SAG, SAGJ from co-founders
The total purchase price is $80m, consisting of a cash payment of $28.1m at closing, and a 7-year subordinated unsecured promissory note of $51.9m. The acquisition enables SPI
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.